Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin.
Ingrid M BistervelsRoisin BavaliaJan Beyer-WestendorfArina J Ten Cate-HoekSebastian M SchellongMichael J KovacsNicolas FalvoKarina MeijerDominique StephanWim G BoersmaMarije Ten WoldeFrancis CouturaudPeter VerhammeDominique BrisotSusan R KahnWaleed GhanimaKarine MontaclairAmanda HugmanPatrick CarrollGilles PernodOlivier SanchezEmile FerrariPierre-Marie RoyMarie-Antoinette Sevestre-PietriSimone BirocchiHilde Skuterud WikBarbara A HuttenMichiel CoppensChristiane NaueMichael A GrossoMinggao ShiYong LinIsabelle QuéréSaskia Middeldorpnull nullPublished in: Research and practice in thrombosis and haemostasis (2022)
Contrary to our hypothesis, the prevalence of PTS tended to be higher in patients treated with edoxaban compared with warfarin. No differences in QoL were observed. Further research is warranted to unravel the role of anticoagulant therapy on development of PTS.